Hanmi Pharm Achieves Record-High Revenue and Operating Profit Last Year

Hanmi Pharm posted its highest results since its founding last year.

According to the pharmaceutical industry on February 5, Hanmi Pharm's consolidated operating profit for last year was provisionally tallied at 257.8 billion won, up 19.2% from a year earlier. Revenue increased 3.5% year-on-year to 1.5475 trillion won, and net profit rose 33.9% to 188.1 billion won.

In the fourth quarter of last year, operating profit was 83.3 billion won, up 173.4% from the same period a year earlier, while revenue and net profit came in at 433 billion won and 55 billion won, respectively.

Headquarters of Hanmi Pharm in Songpa-gu, Seoul. Hanmi Pharm

원본보기 아이콘

Hanmi Pharm analyzed that its performance was driven by solid growth of key products such as Rosuzet, increased revenue from clinical sample supply and royalties from its partner Merck & Co. (MSD) in the United States, and the normalization process at Beijing Hanmi.

In the outpatient prescription segment, Hanmi Pharm recorded revenue of 1.0836 trillion won last year. The dyslipidemia combination drug Rosuzet generated prescription sales of 227.9 billion won, up 8.4% from the previous year, while the hypertension combination product line Amozaltan Family posted sales of 145.4 billion won.

Beijing Hanmi Pharmaceutical, Hanmi Pharm's local subsidiary in China, surpassed 400 billion won in annual revenue for the first time last year, underpinning the overall results. Sales of respiratory disease medicines such as Yianping and Yitanjing expanded on the back of inventory depletion in Chinese distribution channels and seasonal peak demand.

Hanmi Fine Chemical, an affiliate specializing in active pharmaceutical ingredients, posted revenue of 91.3 billion won last year, and its fourth-quarter revenue was 28.3 billion won, up 36.8% from the same period a year earlier.

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.